We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Genome Sequencing Enables Discovery of Mutation Leading to Prader-Willi Syndrome, with Link to Autism

By LabMedica International staff writers
Posted on 09 Oct 2013
Highly accurate whole genome sequencing technology has played a pivotal role in identifying a mutation involved in causing Prader-Willi Syndrome, helping to resolve a diagnostic conundrum.

Prader-Willi Syndrome (PWS) is a rare (around 1:15,000) genetic disorder that leads to poor muscle tone, low levels of sex hormones, and a constant feeling of hunger often leading to obesity. More...
It occurs in males and females equally, and affects all races. The whole genome sequencing technology of Complete Genomics, Inc. (Mountain View, CA, USA), subsidiary of BGI-Shenzhen, was used in the identification of a point mutation causing PWS, a discovery that helped resolve a diagnostic conundrum for four young male patients who tested PWS-negative as infants.

The study, published September 29, 2013, in the journal Nature Genetics, is a collaborative effort of researchers at Baylor College of Medicine (BCM; Houston, TX, USA), the Jan and Dan Duncan Neurological Research Institute (Duncan NRI; Houston, TX, USA), and the Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (Houston, TX, USA).

The first patient tested PWS negative by age one year, but over the next 12 years began to manifest some of the typical PWS symptoms. Complete Genomics’ sequencing service was used in an analysis determining the genetic basis of his symptoms: a single mutation, a base deletion, was identified in the protein-coding MAGEL2 gene, in a section of chromosome 15 previously linked to PWS, and in a difficult to sequence GC rich region. It proved to be a frame-shift deletion, truncating mutation, which disrupts the MAGEL2 protein product. As MAGEL2 is only known to be expressed from the paternal gene allele (the maternal allele being silenced), it was also important to determine whether the mutation was on the maternal or paternal version of chromosome 15. In this case, the MAGEL2 mutation was confirmed to be on the paternal allele using a modified version of Complete Genomics’ Long Fragment Read technology.

To further investigate MAGEL2’s role in PLW, the researchers reviewed over 1,200 exome sequencing reports, searching for other patients with loss-of-function mutations in that gene. Three additional patients were identified – one with classic PWS, the other two with PWS-like symptoms. However, all had negative PWS tests as infants. All four patients were also diagnosed with autism spectrum disorder (ASD) and intellectual disability. These findings suggest that MAGEL2 is a new gene causing complex ASD and that MAGEL2 loss of function can contribute to several aspects of the PWS phenotype.

“This is the first study to show that point mutations can cause Prader-Willi Syndrome,” said Dr. Schaaf, assistant professor of molecular and human genetics at BCM and faculty member at the Duncan NRI; “This is an important development that increases our understanding of this complex disorder, and also gives four boys a diagnosis, which they and their parents have sought for many years.” “It also underscores the importance of being able to distinguish between maternal and paternal variants because only patients who had point mutations on the paternal copy of the MAGEL2 gene would experience the disorder,” added Dr. Brock Peters, director of research at Complete Genomics.

Related Links:

Complete Genomics
Baylor College of Medicine
The Jan and Dan Duncan Neurological Research Institute (of Texas Children's Hospital)



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Immunofluorescence Analyzer
IFA System
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.